Side-by-side · Research reference
CortagenvsMazdutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/35 cited
BPhase 3HUMAN-REVIEWED19/62 cited
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
01Mechanism of Action
Parameter
Cortagen
Mazdutide
Primary target
Cerebral cortex tissue — molecular targets under investigation
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Pathway
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Downstream effect
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Feedback intact?
—
Yes — physiological receptor-mediated signaling preserved
Origin
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Antibody development
—
—
02Dosage Protocols
Parameter
Cortagen
Mazdutide
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
—
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
—
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
—
Phase 2 studied dose
—
Dose escalation
—
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
Duration (trials)
—
24–48 weeks
Population
—
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
03Metabolic / Fat Loss Evidence
Parameter
Cortagen
Mazdutide
Percentage body weight loss
—
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
Responder rate (≥10% loss)
—
Not explicitly reported in available abstracts
Visceral fat
—
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
Glycemic improvement
—
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
Key publications
—
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
04Side Effects & Safety
Parameter
Cortagen
Mazdutide
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
—
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
—
Human safety data
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
—
Gastrointestinal symptoms
—
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
Injection site reactions
—
Erythema, pruritus, local discomfort
Hypoglycemia
—
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
Cardiovascular effects
—
Increased heart rate (glucagon effect, transient)
Pancreatitis risk
—
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
Thyroid C-cell tumors
—
Black box warning for GLP-1 class (rodent data); human relevance unclear
Gallbladder disease
—
Cholelithiasis, cholecystitis (rapid weight loss effect)
Tolerability
—
Generally well-tolerated; GI effects diminish with dose titration
Absolute Contraindications
Cortagen
—Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Relative Contraindications
Cortagen
—Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
05Administration Protocol
Parameter
Cortagen
Mazdutide
1. Preparation
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
2. Injection site
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
3. Timing
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
4. Storage
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
5. Needle technique
—
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.